Publications en collaboration avec des chercheurs de Hospital Morales Meseguer (137)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  4. Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates

    Brain Sciences, Vol. 14, Núm. 6

  5. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

  6. State of the scientific evidence and recommendations for the management of older patients with gastric cancer

    Journal of Geriatric Oncology, Vol. 15, Núm. 3

  7. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial

    World Journal of Gastrointestinal Oncology, Vol. 16, Núm. 2, pp. 386-397

2023

  1. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study

    Oncologist, Vol. 28, Núm. 11, pp. 986-995

  2. Clinicians’ and Advanced Cancer Patients’ Estimates of Treatment Efficacy and Toxicity in Oncologic Treatment

    Healthcare (Switzerland), Vol. 11, Núm. 15

  3. Decoding risk: Caravaggio's insights into risk factors for anticoagulation in cancer-associated thrombosis

    European Journal of Internal Medicine

  4. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  5. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500

  6. Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3492-3500

  7. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  8. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin

    Biomedicine and Pharmacotherapy, Vol. 168

  9. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

  10. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells

    Frontiers in Molecular Biosciences, Vol. 10

2022

  1. A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study

    Journal of Pain Research, Vol. 15, pp. 2181-2196

  2. A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge

    ESMO Open, Vol. 7, Núm. 1

  3. Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic

    Supportive Care in Cancer, Vol. 30, Núm. 4, pp. 3363-3370